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Triple-negative breast cancer (TNBC) is an aggressive malignancy with a poor prognosis despite the high rates of response to
chemotherapy. This scenario highlights the need to develop novel therapies and/or treatment strategies to reduce the mortality
associated with TNBC. The neoadjuvant setting provides a model for rapid assessment of treatment eﬃcacy with smaller patient
accruals and over shorter periods of time compared to the traditional adjuvant setting. In addition, a clear surrogate endpoint
of improved survival, known as pathologic complete response, already exists in this setting. Here, we review current data from
completed and ongoing neoadjuvant clinical trials for TNBC.
1.Introduction
Triple-negative breast cancer (TNBC) is deﬁned histologi-
cally as invasive carcinoma of the breast that lacks staining
for estrogen receptor, progesterone receptor, and HER2/neu.
Approximately 15–20% of breast cancers illustrate this phe-
notype [1]. TNBC is associated with high proliferative rates,
early recurrence, and poor survival rates. This aggressive
diseaseisinsensitivetowidelyusedtargetedtherapiessuchas
trastuzumabandendocrinetherapies,tamoxifenandaroma-
tase inhibitors, which have been eﬀective at reducing breast
cancer mortality. Younger women and women of African
descent have a high prevalence of TNBC [1]. There are lim-
ited and often ineﬀective therapeutic treatment options for
patients with stage IV TNBC.
2. The Concept of Neoadjuvant Chemotherapy
The use of neoadjuvant chemotherapy for patients with
locally advanced breast cancer has increased signiﬁcantly
over several decades. Neoadjuvant chemotherapy was ﬁrst
used in patients with unresectable or marginally resectable
breast cancer [2, 3]. The results from initial studies showed
high rates of tumor response and regression. Additional clin-
ical trials were performed with the primary objective of
determining whether breast conserving surgery could be of-
feredafterneoadjuvantchemotherapytopatientswhowould
have traditionally required mastectomy.
The National Surgical Adjuvant Breast and Bowel Project
(NSABP) B-18 study randomized 1,523 women with opera-
ble breast cancer to receive 4 cycles of adriamycin and cyclo-
phosphamide either in the preoperative or postoperative set-
ting [4]. This study showed that neoadjuvant chemotherapy
improved breast conservation rates (67.8% versus 59.8%).
Although there was no diﬀerence in overall survival (OS)
between neoadjuvant and adjuvant therapy groups, patients
treated in the neoadjuvant setting whose tumors obtained a
pathologic complete response (pCR) at surgery (deﬁned as
no histologic evidence of invasive tumor cells in the breast)
showed improved disease-free survival (DFS) and OS rates2 International Journal of Breast Cancer
compared to those with residual disease. The association of
pCR with survival outcomes has also been observed by other
neoadjuvant studies [5, 6]. Thus, pCR is now considered to
be an important endpoint in clinical trials assessing the ef-
ﬁcacy of neoadjuvant chemotherapy.
Justasbreastcancerhasbeenclassiﬁedintosubtypeswith
distinct gene expression and associated clinical outcomes [7,
8], response to neoadjuvant chemotherapy by subtype is also
unique.Forexample,thepCRrateforpatientswithhormone
receptor (HR)-positive tumors was 8% after anthracycline-
based or anthracycline/taxane-based chemotherapy [9]. In
contrast, the pCR rate for TNBC patients undergoing similar
therapies was found to be 25% [9], despite poorer overall
outcome when compared to those with HR-positive disease.
This phenomenon, termed the “triple negative paradox,”
is supported by data from several notable clinical studies;
however,thereasonforthisphenomenonislargelyunknown
[5, 6, 10].
Recognizing the clinical heterogeneity of breast cancer,
a group of investigators sought to determine if diﬀerent
molecular subclasses of breast cancer responded diﬀerent-
ly to anthracycline- and paclitaxel-containing preoperative
chemotherapy [10]. To answer this question, ﬁne needle
aspirations of breast cancer were obtained from 82 patients
prior to initiation of neoadjuvant paclitaxel followed by
5-ﬂuorouracil, doxorubicin, and cyclophosphamide chem-
otherapy. Gene expression proﬁling was performed and
each breast cancer was assigned a unique molecular class—
luminal (n = 30), basal-like (n = 22), and HER2-positive
(HER2+; n = 20) breast cancers. The rates of pCR, deﬁned
asnoresidualinvasivecancerinthebreastandaxillarylymph
nodes, diﬀered signiﬁcantly among these three molecular
classes of breast cancer. Basal-like breast cancers, of which
greater than 85% were either estrogen receptor and/or
HER2 negative, were associated with high rates of pCR 45%
(95% conﬁdence interval (CI) 24–68). Similarly, the HER2+
subgroup was associated with high rates of pCR (45%, CI
23–68), whereas those with luminal tumors illustrated much
lower pCR rates (6%, CI 1–21). Genes associated with pCR
were examined between the basal-like and HER2+ subtypes,
and there was no overlap in these gene sets. This data
indicates that genes associated with chemotherapy sensitivity
likely diﬀer between these two molecular subgroups of breast
cancer.
Not only has response to preoperative chemotherapy
been shown to diﬀer by breast cancer subtype, but also
prognosis, particularly as it relates to residual disease follow-
ing neoadjuvant therapies. Carey et al. sought to examine
the relationship between neoadjuvant response and long-
term end points, including distant DFS (DDFS) and OS [6].
In this landmark study, 107 patients with stage II-III breast
cancer were treated with 4 cycles of neoadjuvant doxoru-
bicin/cyclophosphamide chemotherapy (75% also received
preoperative taxanes) between the years 1998 and 2003.
Breastcancersubtypesweredeﬁnedasfollowsusingimmun-
ohistochemistry-surrogate markers: 34% for luminal A
(HER2−/HR-positive), 24% for luminal B (HER2+/HR-
positive), 10% for HER2+ (HER2+/HR negative), and
32% for basal-like (HER2−/HR negative). Similar to the
Rouzier et al. study, pCR was higher among patients with
basal-like and HER2+ breast cancer (27% and 36%, resp.)
and only 7% in luminal breast cancers (P<0.05 in both
comparisons). Although pCR was higher among those with
HER2+ and basal-like breast cancer, patients of either sub-
typeexperiencedinferiorDDFSandOScomparedtoluminal
breast cancer patients. Overall, only 2 of 17 patients across
subtypeswithpCRrelapsed.Thus,theoverallworseoutcome
observed within basal-like and HER2+ subtypes was due to
higher relapse rates among those with residual disease.
A subsequent analysis conducted by Liedtke et al. per-
formed a similar analysis that evaluated 1,118 patients who
received neoadjuvant anthracycline and/or taxane-based
chemotherapy at MD Anderson Cancer Center between
the years 1985–2004 [5]. In this cohort of patients, 255
patients (23%) were classiﬁed as having TNBC, while
863 patients (77%) had non-TNBC. Consistent with prior
reports, increased pCR rates were observed for patients with
TNBC compared with non-TNBC (22% versus 11%; odds
ratio[OR]=1.53,P = 0.034).DespitethisdiﬀerenceinpCR,
a signiﬁcant decrease in 3-year RFS and OS was observed
for patients with TNBC compared with non-TNBC (63%
versus 76%, P = 0.0001 and 74% versus 89%, P = 0.0001
resp.). Moreover, if a pCR was achieved, patients with TNBC
and non-TNBC had similar survival (HR = 1.7, P = 0.24).
Conversely, patients with residual disease experienced worse
OS if they had TNBC compared with non-TNBC (HR =
1.5; P<0.0001). This data supports the continued eﬀorts
to identify novel neoadjuvant approaches that will enhance
pCR rates among women with TNBC (and non-TNBC). In
parallel, there is a need to develop therapeutic strategies for
TNBC with residual disease following neoadjuvant therapy.
3.OngoingandCompleted Neoadjuvant
TherapeuticStrategiesforTNBC
As per the most recent National Cancer Comprehensive
Network (NCCN) guidelines for the treatment of invasive
breast cancer, women with stage IIA–IIIA breast cancer who,
with the exception of tumor size, are otherwise candidates
for breast-conserving therapy, may be considered for preop-
erativechemotherapywithanumberofanthracyclineand/or
taxane-based regimens (http://www.nccn.com/). While these
chemotherapy regimens remain the mainstay to treat oper-
able TNBC [11], salient eﬀorts are being made to improve
outcomes for women diagnosed with this aggressive disease.
Some of these strategies include the addition of chemothera-
peuticagentstotheanthracycline/taxanebackbone,aswellas
the incorporation of biologic and targeted agents to standard
regimens. Many of the completed and ongoing clinical trials
testing novel neoadjuvant treatment strategies for TNBC will
be reviewed here (see Table 1).
4. Chemotherapy
Buildingonexperiencesinthemetastaticsettingwhereselect
combination chemotherapies have led to improved breast
canceroutcomescomparedtosingleagentregimens[20,21],International Journal of Breast Cancer 3
Table 1: Summary of completed neoadjuvant chemotherapy trials.∗
Clinical trials Design Drugs Population pCR rate
Silver et al. [12] Phase II single arm Cisplatin × 4 TNBC 6/28 (21%)
Byrski et al. [13] Retrosp. All; CMF; AD; AC/FAC; cisplatin BRCA1 mut.
All: 24/102 (24%)
CMF: 1/14 (7%)
AD: 2/25 (8%)
AC/FAC: 11/51 (22%)
Cisplatin: 10/12 (83%)
Bear et al. [14] Phase III random.
Arm 1A: D × 4 → AC × 4
Arm 1B: D + X × 4 → AC × 4
Arm 1C: D + G × 4c y c l e s→ Ac ×
4
HER2−
Arm 1A: 102/393 (26%)
Arm 1B: 91/390 (23%)
Arm 1C: 106/388 (27%)
Alba et al. [15] Phase II random.
Arm A: EC × 4c y c l e s→ D × 4
Arm B: EC × 4c y c l e s→ D+
Carbo × 4
Basal-like Arm A: 14/46 (30%)
Arm B: 14/47 (30%)
Zelnak et al. [16] Phase II random. Arm A: D × 4c y c l e s→ X × 4;
Arm B: D + X × 8c y c l e s . HER2−
Arm A: 2/25 (8%)
Arm B: 3/26 (12%)
Arm A/B (TNBC): 4/21 (19%)
Von Minckwitz et al. [17]
Huober et al. [18] Phase III random.
Arm 1 (responder): TAC × 4
Arm 2 (responder): TAC × 6
Arm 3 (nonresponder): TAC × 4
Arm 4 (nonresponder): VX × 4
Any breast
cancer
Arm 1–4
TNBC: 77/198 (39%)
Non-TNBC: 22/147 (15%)
Baselga et al. [19] Phase II single arm Ixabepilone × 4 Any breast
cancer
TNBC: 11/42 (26%)
Non-TNBC: 18/119 (15%)
∗TNBC: triple-negative breast cancer; pCR: pathological complete response; M: methotrexate; F: 5-ﬂuorouracil; Retrosp.: retrospective study; T: paclitaxel;
Carbo: carboplatin; D: docetaxel; C: cyclophosphamide; A: doxorubicin; E: epirubicin; X: capecitabine; G: gemcitabine; V: vinorelbine.
several neoadjuvant studies have sought to determine the
additive beneﬁt of incorporating novel chemotherapeutics
withstandardanthracyclineand/ortaxanes.Theseadditional
chemotherapeutics have included antimetabolites, platinum
agents, and novel microtubule stabilizing agents.
4.1. Antimetabolites. The recently reported National Surgical
Adjuvant Breast and Bowel Project (NSABP) B-40 protocol
asked two fundamental questions: (1) was the addition of
the antimetabolite either capecitabine (X) or gemcitabine
(G) to docetaxel (T) followed by AC, and/or (2) does the
addition of bevacizumab to docetaxel/anthracycline-based
regimens increase pCR rates for women with HER2-negative
breast cancer [14]. While this study was not restricted with
women with TNBC, 41% of the 1,206 patients had HER2-
negative/HR-negative breast tumors (thus, triple negative).
Complete clinical response as assessed by physical exam
was not signiﬁcantly diﬀerent by treatment arm (P>0.4).
Similarly, no statistically signiﬁcant diﬀerence was observed
for pCR in both breast and lymph nodes across all treatment
arms: T → AC 26%; TX → AC 23.3%; TG → AC 27.3%
(P>0.4; Table 1). Toxicity was reported for 1,191 pa-
tients, including all grade 3 and 4 adverse events and was
numerically higher for the TX → AC (55% Grade 3 and 14%
Grade 4) and TG → AC (61% Grade 3 and 12% Grade 4)
arms compared to the T → AC arm (48% Grade 3 and 7%
Grade 4).
A second study sought to determine the additional
beneﬁt of preoperative capecitabine to docetaxel—either
sequentially or in combination—to treat women with
HER2-negative breast cancer [16]. In this study, 51 women
were treated with either 4 cycles of docetaxel followed by
4 cycles of capecitabine (Arm A, n = 25) or 8 cycles of
concurrent docetaxel/capecitabine. Median tumor size was
6.1cm, 68% of patients were clinically lymph node positive,
and 41.2% had TNBC. Overall, treatment was well-tolerated
with expected grade 3 and 4 toxicities (15.7% neutropenia,
5.9% neuropathy, and 3.9% neuropathy). For the entire
study cohort, pCR rates were 8% and 11.5% for Arm A and
B, respectively. Among those with TNBC, pCR rate in both
arms combined was 19%.
While the results of these two studies illustrate modest,
at best, activity for the addition of antimetabolites to anthra-
cycline/taxane and/or taxane-based therapy, results as they
pertain to TNBC should be interpreted with caution as only
40% of study populations were classiﬁed as triple negative.
In addition, and given the higher toxicity proﬁle associated
with doublet chemotherapy, biomarker strategies to both
enrich for responders and minimize toxicities associated
with antimetabolites should be considered and incorporated
into future neoadjuvant studies examining combination
strategies.
4.2. Platinum Therapy. Given the inherent genomic insta-
bility of TNBC/basal-like with and without BRCA germline
mutations and respectable sensitivity to platinums in the
metastatic setting [22–24], several neoadjuvant studies have
evaluated these agents as monotherapy or in diﬀerent
combination strategies. In Silver et al., 28 women with Stage
II or III TNBC (of which 2 harbored a germline BRCA14 International Journal of Breast Cancer
Table 2: Summary of neoadjuvant bevacizumab-based chemotherapy trials.∗
Clinical trials Design Drugs Population Status pCR rate
Gerber et al. [31]
(GeparQuinto) Phase III Arm 1: EC × 4 → D × 4
Arm 2: EC+ Bev × 4 → D+B e v× 4 TNBC Completed Arm 1: 96/342 (28%)
Arm 2: 119/327 (36.4%)
Bear et al. [14]
(NSABP B-40)
Phase III
random
Arm 1A-C:
Anthracycline-taxane-based
chemotherapy
Arm 2A-C:
Anthracycline-taxane-based
chemotherapy + Bev
HER2− Completed
All Arms Bev: 203/588 (35%)
All Arms/no Bev: 168/592 (28%)
TNBC Bev: 121/236 (51%)
TNBC/no Bev: 115/243 (47%)
HR+ Bev: 82/352 (23%)
HR+/no Bev: 53/349 (15%)
CALGB-40603 Phase II
random
Arm 1: T → AC
Arm 2: T + Bev → AC + Bev
Arm 3: T + Carbo → AC
A r m4 :T+C a r b o+B→ AC + Bev
TNBC Ongoing —
∗TNBC: triple-negative breast cancer; pCR: pathological complete response; Bev: bevacizumab; T: paclitaxel; Carbo: carboplatin; D: docetaxel; C:
cyclophosphamide; A: doxorubicin; E: epirubicin.
mutation) were treated with 4 cycles of cisplatin monother-
apy 75mg/m2 every 21 days. The pCR rate was 21% (6/28),
and the partial and complete clinical response was 64%
(18/28). Several variables were associated with response:
young age, low BRCA1 mRNA expression, BRCA1 promoter
methylation, p53 nonsense or frameshift mutations, and a
geneexpressionsignatureofE2F3activation.Inasubsequent
study of two Polish series of women with BRCA1-mutated
breast cancer largely triple-negative treated with cisplatin
monotherapy (75mg/m2 every 21 days), the pCR rates were
as high as 80–90% [13, 25]. Further studies are needed to
determine if BRCA1 mutations are predictive of cisplatin
beneﬁt in TNBC.
The recently reported GEICAM 2006-03-A study sought
to determine the additional beneﬁt of carboplatin to
conventional neoadjuvant chemotherapy in women with
TNBC/basal-like breast cancer patients (deﬁned as ER−/
PR−/HER2− and cytokeratin 5/6+ and/or epithelial growth
factor receptor [EGFR]+) [15]. In this Phase II multicenter
study, 94 patients with ≥2cmtumorswererandomizedto
receiveepirubicin/cyclophosphamidefor4cyclesfollowedby
eitherdocetaxelwithorwithoutcarboplatinfor4cycles.pCR
in both the breast and axilla was reported to be 30% in both
arms; Grade 3/4 toxicities between arms were similar (54%
and 53%).
Ongoing studies will continue to help us deﬁne the
role, timing, and optimal patient population of platinums
in the preoperative treatment of TNBC. As an example,
the Cancer and Leukemia Group B (CALGB) 40603 clin-
ical trial is actively enrolling patients to standard anthra-
cycline/taxane-based neoadjuvant therapy without carbo-
platin (NCT00861705). Pretreatment breast core biopsies
are required at study entry. Both the clinical outcomes and
correlative endpoints of this study will help guide future use
of platinum agents in this setting.
4.3. Microtubule Stabilizing Agents. Ixabepilone, a novel
semisynthetic antineoplastic agent derived from natural
epothilones and their analogs, promotes tumor cell death by
stabilizing microtubules and inducing cell cycle arrest and
subsequent apoptosis. A large, randomized, Phase III study
illustrated improvement in PFS by the addition of ixabepi-
lone to capecitabine to treat women with metastatic breast
cancer, including those with TNBC [26]. This has led inves-
tigators to evaluate the beneﬁt of ixabepilone in the neoad-
juvant treatment of invasive breast cancer not amenable to
breast conservation surgery [19]. In this study, 161 women
with inoperable breast cancer (of which 42 [26%] were
triple negative) were treated with 4 or fewer cycles of single
agent ixabepilone. pCR rates in the breast were 18% for the
entire study population; 22% in ER negative/HER2 negative;
46.1% in ER negative/HER2+; 10.6% in ER positive/HER2-
negative; 20% in ER positive/HER2+. Gene expression stud-
ies from pretreatment core breast biopsies conﬁrmed the
inverse relationship between ER expression and ixabepilone
sensitivity. An ongoing clinical trial evaluating diﬀerential
responses to neoadjuvant paclitaxel versus ixabepilone fol-
lowing AC chemotherapy in the preoperative setting of early
stage breast cancer is eagerly awaited (NCT00455533).
5. Antiangiogenic Agents
It is well established in both the laboratory and clinical set-
tingsthatangiogenesisisakeymediatorofbreastcancerpro-
gression [27]. Multiple studies have evaluated the beneﬁt of
targetingvascularendothelialgrowthfactorreceptor(VEGF)
with the humanized monoclonal antibody, bevacizumab
(Avastin, Genentech/Roche). Although results were more
impressive in the E2100 study as compared to others, the
addition of bevacizumab has consistently led to improve-
ments in response rates, while PFS beneﬁt has been more
modest [28–30]. However, as some beneﬁt has been seen in
the TNBC subset and given the relative paucity of “targets”
in TNBC, several investigators have sought to determine
the beneﬁt of targeting VEGF with bevacizumab in the
neoadjuvant setting (see Table 2).
The GeparQuinto study was designed to determine
the beneﬁt to adding bevacizumab to anthracycline/taxane-
based preoperative chemotherapy among 1,948 women with
HER2-negative breast cancer [32]. Patients were randomizedInternational Journal of Breast Cancer 5
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Figure 1: Clinical trial design schematic.
to receive 4 cycles of epirubicin/cyclophosphamide (EC)
followed by 4 cycles of docetaxel (D) with or without
bevacizumab. Approximately 35% of patients in both arms
had TNBC. For the entire study cohort, there was no statis-
tical signiﬁcant diﬀerence in pCR (deﬁned as no inva-
sive/noninvasive residual in breast and nodes) between
groups (15% EC → D and 17.5 EC → Dp l u sb e v a c i z u m a b ) .
In a predeﬁned stratiﬁcation by subtype, patients with
TNBC had a signiﬁcantly higher likelihood of pCR by the
addition of bevacizumab compared to the other subtypes
(OR = 1.42). In a subsequent analysis in TNBC patients only
(n = 684)reported atASCO2011 annualmeeting, pCR rates
in both breast and lymph nodes were higher for patients
who received EC → T plus bevacizumab compared to EC
→ D alone (36.4% versus 28%, P = 0.021) [31]. A large
biomarker program is ongoing to try to identify subgroups
withinTNBCwhoachievegreaterbeneﬁtfrombevacizumab.
In addition to evaluating the beneﬁt of adding antime-
tabolites to standard anthracycline/taxane-based chemother-
apy, the recently reported NSABP B-40 study also sought to
determine if the addition of bevacizumab would enhance
pCR rates for >1,200 women with HER2-negative breast
cancer [14]. In this study, patients were treated with
AC followed by docetaxel with or without bevacizumab.
Complete clinical responses were higher among women who
received bevacizumab (64.3 versus 55.8%, P = 0.006). This
eﬀect was more dramatic in those with HR-positive breast
cancer (64.5% versus 53.7% with and without bevacizumab,
resp., P = 0.007) compared to those with TNBC (63.9%
versus 59.1% with and without bevacizumab, resp., P =
0.371). Similar to clinical response, pCR was higher for
patients who received bevacizumab compared to those who
did not (34.5 versus 28.4%; OR = 1.33, P = 0.027), and
the positive eﬀect was more prominent in patients with HR-
positive tumors (OR = 1.7, P = 0.008) as compared to those
with TNBC (OR = 1.17, P = 0.44). Given the apparent
diﬀerences in response rates between the GeparQuinto and
B40 studies within TNBC, the results of the ongoing CALGB
study 40603 (NCT00861705) evaluating both the addition to
platinum and bevacizumab to standard anthracycline/taxane
chemotherapy are eagerly awaited.
6.NovelTargetedStrategies:
SmallMoleculeInhibitors
In addition to advances in combination chemotherapeutics
and antiangiogenic agents, substantial eﬀort is being made
to optimize preoperative response rates through the use of
novel agents targeting important oncogenic signaling path-
ways in breast cancer. These strategies include the inhibi-
tion of mammalian target of rapamycin (mTOR), histo-
ne deacetylase (HDAC), and poly-ADP-ribose polymerase
(PARP).
Given that activation of the PI3K/mTOR pathway acti-
vation occurs frequently in TNBC, investigators sought to
determine the beneﬁt of adding RAD001 (Novartis), an
mTORinhibitor,toneoadjuvantanthracycline/taxanechem-
otherapy [33]. Fifty patients with TNBC were randomized
to receive paclitaxel weekly for 12 weeks with or without
weekly RAD001 for 12 weeks, both followed by 5FU/epi-
rubicin/cyclophosphamide (FEC) every 3 weeks for 4 cycles.
Although pCR rates did not diﬀer by treatment arm (30.4%
versus 25.9%, P = 0.761), investigators collected breast
tumor biopsies to evaluate molecular changes in the PI3K
pathway at baseline, 48 hours, 12 weeks after-therapy and at
surgery. Ongoing correlative science studies are likely to help
reﬁne the selection of patients most likely to respond to these
targeted agents.
Epigenetic mechanisms are another potential target for
TNBC. For example, studies have shown that the loss of ER-
α by gene methylation might be occurring in ER-negative
breast tumors, and that demethylation could restore the
expression of ER and sensitize the tumor cells to hormonal
therapies [34]. In addition, preclinical and early phase clini-
cal studies have illustrated eﬃcacy for targeting endocrine-
resistant breast cancers with HDAC inhibitors [34, 35].
Building on these results, an ongoing study (NCT00262834)
is evaluating change in tumor morphology, tissue and blood
(peripheral blood mononuclear cells) histone acetylation,
and safety of short term exposure to the HDAC inhibitor, vo-
rinostat (Merck), for newly diagnosed breast cancers. These
results will undoubtedly inform future trials evaluating6 International Journal of Breast Cancer
HDAC inhibitors in the neoadjuvant treatment of breast
cancer.
Finally, the I-SPY 2 trial (investigation of serial studies to
predict your therapeutic response with imaging and molec-
ular analysis 2) is a multicenter, neoadjuvant study projected
to enroll over 800 women with breast cancer of all pheno-
types(NCT01042379).Thistrialisintegratingnovelimaging
and biomarker analysis to improve response prediction to a
varietyofnoveltargetedagentsincombinationwithstandard
chemotherapeutics. Pertinent to TNBC, a subset known to
share clinicopathologic features with BRCA-deﬁcient breast
cancers [36] will be treated with the PARP inhibitor, ABT-
888.
7. Conclusions
Although TNBC has an overall poor prognosis, TNBC pa-
tientsundergoingneoadjuvantchemotherapyhaveimproved
breast conservation rates and high response rates. In this
setting, pCR is an appropriate endpoint for predicting im-
proved longer-term outcome. However, this endpoint is only
achieved by current treatment strategies in 20–40% of the
cases. Thus, we recommend that patients presenting with
operable TNBC be encouraged to participate in neoadjuvant
clinical trials since there are a number of novel targeted
agents that are currently being evaluated.
Treatment in the neoadjuvant setting provides an ideal
model for evaluating the eﬃcacy of new targeted therapies
for TNBC. Such an approach allows for smaller patient
accrual, shorter timeframes to obtain results and routine tis-
sue collection for correlative studies compared to traditional
adjuvant trials (see Figure 1). Neoadjuvant trials allow for
more rapid evaluation of novel therapies for TNBC. In addi-
tion, primary tumor core biopsies can be obtained before
initiation of systemic therapy and during therapy for correl-
ative studies to assess the status of particular biomarkers and
test if the presumed targets are being inhibited by these novel
therapies. For example, proliferation-related biomarker Ki-
67 has been shown to be a useful surrogate for response
during or after neoadjuvant endocrine therapy [37].
In closing, there are numerous ongoing clinical neoad-
juvant trials aimed at improving outcome for patients with
TNBC. Moreover, the use of neoadjuvant chemotherapy as
the primary model for clinical research for TNBC will ad-
vance our understanding of molecular response to novel
agents and our ability to eﬃciently assess the eﬃcacy of
promising therapies with the ultimate goal of improving pa-
tient survival.
References
[1] L. A. Carey, C. M. Perou, C. A. Livasy et al., “Race, breast can-
cer subtypes, and survival in the Carolina breast cancer study,”
Journal of the American Medical Association, vol. 295, no. 21,
pp. 2492–2502, 2006.
[2] L. M. Koplin and T. X. O’Connell, “A new approach to the
management of primary unresectable carcinoma of the breast:
is radiation therapy necessary?” American Journal of Clinical
Oncology, vol. 6, no. 5, pp. 599–604, 1983.
[3] L. A. Newman, “Surgical issues and preoperative systemic
therapy,” Cancer Treatment and Research, vol. 141, pp. 79–98,
2008.
[4] B. Fisher, A. Brown, E. Mamounas et al., “Eﬀect of preopera-
tive chemotherapy on local-regional disease in women with
operable breast cancer: ﬁndings from national surgical adju-
vant breast and bowel project B-18,” Journal of Clinical
Oncology, vol. 16, no. 8, pp. 2672–2685, 1998.
[5] C. Liedtke, C. Mazouni, K. R. Hess et al., “Response to neoad-
juvant therapy and long-term survival in patients with triple-
negative breast cancer,” Journal of Clinical Oncology, vol. 26,
no. 8, pp. 1275–1281, 2008.
[6] L. A. Carey, E. C. Dees, L. Sawyer et al., “The triple negative
paradox: primary tumor chemosensitivity of breast cancer
subtypes,” Clinical Cancer Research, vol. 13, no. 8, pp. 2329–
2334, 2007.
[7] C. M. Perou, T. Sørile, M. B. Eisen et al., “Molecular portraits
ofhumanbreasttumours,”Nature,vol.406,no.6797,pp.747–
752, 2000.
[8] T. Sorlie, C. M. Perou, R. Tibshirani et al., “Gene expres-
sion patterns of breast carcinomas distinguish tumor sub-
classes with clinical implications,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 98, no.
19, pp. 10869–10874, 2001.
[9] V. Guarneri, K. Broglio, S. W. Kau et al., “Prognostic value of
pathologic complete response after primary chemotherapy in
relation tohormone receptor statusand other factors,” Journal
of Clinical Oncology, vol. 24, no. 7, pp. 1037–1044, 2006.
[10] R. Rouzier, C. M. Perou, W. F. Symmans et al., “Breast
cancer molecular subtypes respond diﬀerently to preoperative
chemotherapy,” Clinical Cancer Research, vol. 11, no. 16, pp.
5678–5685, 2005.
[11] H. D. Bear, S. Anderson, R. E. Smith et al., “Sequential preop-
erative or postoperative docetaxel added to preoperative dox-
orubicin plus cyclophosphamide for operable breast cancer:
national surgical adjuvant breast and bowel project protocol
B-27,” Journal of Clinical Oncology, vol. 24, no. 13, pp. 2019–
2027, 2006.
[12] D. P. Silver, A. L. Richardson, A. C. Eklund et al., “Eﬃcacy of
neoadjuvantCisplatinintriple-negativebreastcancer,”Journal
of Clinical Oncology, vol. 28, no. 7, pp. 1145–1153, 2010.
[13] T.Byrski,J.Gronwald,T.Huzarskietal.,“Pathologiccomplete
response rates in young women with BRCA1-positive breast
cancers after neoadjuvant chemotherapy,” Journal of Clinical
Oncology, vol. 28, no. 3, pp. 375–379, 2010.
[14] H. D. Bear et al., “The eﬀect on pCR of bevacizumab and/or
antimetabolites added to standard neoadjuvant chemother-
apy: NSABP protocol B-40,” Journal of Clinical Oncology, vol.
29, abstract LBA1005, 2011.
[15] E. Alba et al., “Chemotherapy (CT) with or without carbo-
platin as neoadjuvant treatment in patients with basal-like
breast cancer: GEICAM 2006-03-A multicenter, randomized
phase II study,” Journal of Clinical Oncology, vol. 29, abstract
1015, 2011.
[16] A. B. Zelnak et al., “Final results from randomized phase II
trial of preoperative docetaxel (D) and capecitabine (C)
given sequentially or concurrently for HER2-negative breast
cancers,” Journal of Clinical Oncology, vol. 29, Abstract 1118,
2011.
[17] G. Von Minckwitz, S. K¨ ummel, P. Vogel et al., “Neoadju-
vant vinorelbine-capecitabine versus docetaxel-doxorubicin-
cyclophosphamideinearlynonresponsivebreastcancer:phase
III randomized gepartrio trial,” Journal of the National Cancer
Institute, vol. 100, no. 8, pp. 542–551, 2008.International Journal of Breast Cancer 7
[18] J. Huober, G. Von Minckwitz, C. Denkert et al., “Eﬀect of
neoadjuvant anthracycline-taxane-based chemotherapy in
diﬀerent biological breast cancer phenotypes: overall results
from the GeparTrio study,” Breast Cancer Research and
Treatment, vol. 124, no. 1, pp. 133–140, 2010.
[19] J. Baselga, M. Zambetti, A. Llombart-Cussac et al., “Phase II
genomics study of ixabepilone as neoadjuvant treatment for
breast cancer,” Journal of Clinical Oncology, vol. 27, no. 4, pp.
526–534, 2009.
[20] J. O’Shaughnessy, D. Miles, S. Vukelia et al., “Superior
survivalwithcapecitabineplusdocetaxelcombinationtherapy
in anthracycline-pretreated patients with advanced breast
cancer: phaseIIItrialresults,”JournalofClinicalOncology,vol.
20, no. 12, pp. 2812–2823, 2002.
[21] K.S.Albain,S.M.Nag,G.Calderillo-Ruizetal.,“Gemcitabine
plus paclitaxel versus paclitaxel monotherapy in patients with
metastatic breast cancer and prior anthracycline treatment,”
Journal of Clinical Oncology, vol. 26, no. 24, pp. 3950–3957,
2008.
[ 2 2 ]R .N a t r a j a n ,B .W e i g e l t ,A .M a c k a ye ta l . ,“ A ni n t e g r a t i v e
genomic and transcriptomic analysis reveals molecular path-
ways and networks regulated by copy number aberrations in
basal-like, HER2 and luminal cancers,” Breast Cancer Research
and Treatment, vol. 121, no. 3, pp. 575–589, 2010.
[23] L. A. Carey et al., “TBCRC 001: EGFR inhibition with
cetuximab added to carboplatin in metastatic triple-negative
(basal-like)breastcancer,”JournalofClinicalOncology,vol.26,
abstract 1009, supplement, 2008.
[24] J.. Baselga, “Cetuximab + cisplatin in estrogen receptor-
negative, progesterone receptor-negative, HER2-negative
(Triple-Negative) metastatic breast cancer: results of the
randomized phase II BALI-1 trial,” in Proceedings of the San
Antonio Breast Cancer Symposium, 2010, PD01-01.
[25] T. Byrski, T. Huzarski, R. Dent et al., “Response to neoadju-
vant therapy with cisplatin in BRCA1-positive breast cancer
patients,” Breast Cancer Research and Treatment, vol. 115, no.
2, pp. 359–363, 2009.
[ 2 6 ]E .S .T h o m a s ,H .L .G o m e z ,R .K .L ie ta l . ,“ I x a b e p i l o n ep l u s
capecitabine for metastatic breast cancer progressing after
anthracyclineandtaxanetreatment,”JournalofClinicalOncol-
ogy, vol. 25, no. 33, pp. 5210–5217, 2007.
[27] J. Folkman, “What is the evidence that tumors are angiogen-
esis dependent?” Journal of the National Cancer Institute, vol.
82, no. 1, pp. 4–6, 1990.
[28] K. Miller, M. Wang, J. Gralow et al., “Paclitaxel plus beva-
cizumab versus paclitaxel alone for metastatic breast cancer,”
New England Journal of Medicine, vol. 357, no. 26, pp. 2666–
2676, 2007.
[29] D. W. Miles, A. Chan, L. Y. Dirix et al., “Phase III study
of bevacizumab plus docetaxel compared with placebo plus
docetaxel for the ﬁrst-line treatment of human epidermal
growth factor receptor 2-negative metastatic breast cancer,”
Journal of Clinical Oncology, vol. 28, no. 20, pp. 3239–3247,
2010.
[30] N. J. Robert, V. Di´ eras, J. Glaspy et al., “RIBBON-1: ran-
domized, double-blind, placebo-controlled, phase III trial of
chemotherapy with or without bevacizumab for ﬁrst-line
treatment of human epidermal growth factor receptor 2-
negative, locally recurrent or metastatic breast cancer,” Journal
of Clinical Oncology, vol. 29, no. 10, pp. 1252–1260, 2011.
[31] B. Gerber et al., “Neoadjuvant bevacizumab and anthracy-
cline–taxane-based chemotherapy in 686 triple-negative pri-
mary breast cancers: seconday endpoint analysis of the
GeparQuinto study (GBG 44),” Journal of Clinical On-cology,
vol. 29, abstract 1006, 2011.
[32] G. von Minckwitz, “Neoadjuvant chemotherapy with or with-
out Bevacizumab: primary eﬃcacy endpoint analysis of the
GEPARQUINTO Study (GBG 44),” in Proceedings of the San
Antonio Breast Cancer Symposium, 2010, Abstract S4–6.
[33] A. M. Gonzalez-Angulo et al., “Open label, randomized clini-
caltrialofstandardneoadjuvantchemotherapywithpaclitaxel
followed by FEC (T-FEC) versus the combination of paclitaxel
and RAD001 followed by FEC (TR-FEC)inwomen with triple
receptor-negative breast cancer (TNBC),” Journal of Clinical
Oncology, vol. 29, abstract 1016, 2011.
[34] J. C. Keen, L. Yan, K. M. Mack et al., “A novel histone dea-
cetylaseinhibitor,Scriptaid,enhancesexpressionoffunctional
estrogen receptor α (ER) in ER negative human breast cancer
cells in combination with 5-aza 2 -deoxycytidine,” Breast
Cancer Research and Treatment, vol. 81, no. 3, pp. 177–186,
2003.
[35] M. Lacevic, S. Minton, and M. Schmitt, “Phase II trial of the
HDAC inhibitor, vorinostat, in combination with tamoxifen
for patients with advanced breast cancer who have failed prior
anti-hormonal therapy,” Breast Cancer Research and Treat-
ment, vol. 106, abstract 2097, supplement 1, p. S117, 2007.
[36] W. D. Foulkes, I. M. Stefansson, P. O. Chappuis et al., “Germ-
line BRCA1 mutations and a basal epithelial phenotype in
breast cancer,” Journal of the National Cancer Institute, vol. 95,
no. 19, pp. 1482–1485, 2003.
[37] M. J. Ellis, Y. Tao, J. Luo et al., “Outcome prediction for es-
trogen receptor-positive breast cancer based on postneoadju-
vant endocrine therapy tumor characteristics,” Journal of the
National Cancer Institute, vol. 100, no. 19, pp. 1380–1388,
2008.